Markets:

Overview

News

Currencies

International

Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

225.87 -2.82 (-1.23%)

Streaming Delayed Price Updated: 11:45 AM EDT, Sep 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 3 Next >

Meet the Magnificent Momentum-Driven ETF Obliterating the S&P 500 in 2026 ↗

September 13, 2026

This actively managed exchange-traded fund is producing spectacular returns for investors thanks to its unique strategy.

Via The Motley Fool

Topics ETFs Stocks

If You Invest $10,000 in the Vanguard U.S. Momentum Factor ETF (VFMO) Today, Here's What History Says You Could Have in 20 Years ↗

August 30, 2026

This relatively unknown ETF has outperformed the Russell 3000 and the S&P 500 over many periods.

Via The Motley Fool

Topics ETFs Stocks

The Best ETF for the Investor Who Wants to Beat the Market While Barely Lifting a Finger ↗

August 08, 2026

You don't have to pick individual stocks to have a good shot at outperforming the market.

Via The Motley Fool

Topics ETFs

Lyft Draws Investor Attention After Wedbush Downgrades Stock Amid Autonomous Vehicle Risks ↗

December 19, 2025

Via Stocktwits

American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act ↗

December 03, 2025

Via Stocktwits

Meet the Magnificent Vanguard ETF Crushing the S&P 500 in 2026, Thanks to Its Unique Momentum-Driven Strategy ↗

August 04, 2026

This fund has just $2 billion in assets, but it might deserve more attention because of its solid returns.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

2 Vanguard Index Funds Are Crushing the S&P 500 This Year ↗

July 24, 2026

These Vanguard index funds have trounced the overall U.S. stock market this year.

Via The Motley Fool

Topics ETFs Government Stocks

2 Vanguard ETFs Beating the S&P 500 With a Momentum-Driven Strategy ↗

July 10, 2026

Vanguard's factor ETF lineup doesn't get a lot of attention. Its track record of market-beating returns suggests it should.

Via The Motley Fool

Topics ETFs Stocks

3 Vanguard ETFs That Can Turn $1,000 per Month Into Over $1 Million ↗

June 30, 2026

Vanguard has exchange-traded funds that combine low fees with track records of attractive long-term returns.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Meet the Magnificent Vanguard ETF Obliterating the S&P 500 in 2026 Because of Its Unique Momentum-Driven Strategy ↗

June 19, 2026

Most investors have probably never heard of this Vanguard ETF, but it routinely beats the market.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

This Vanguard ETF Has Outperformed the Company's S&P 500 Fund for Years. Most Investors Have Never Heard of It. ↗

June 11, 2026

Most people know Vanguard for its low-cost index funds. This smaller, actively managed ETF has been able to beat the S&P 500 for more than eight years.

Via The Motley Fool

Topics ETFs Stocks

WIN Advisors Cuts Its FTC Stake by $10.6 Million -- Here's What Investors Should Know ↗

May 01, 2026

This fund tracks a rules-based index targeting U.S. large-cap growth stocks, using a systematic approach to portfolio construction.

Via The Motley Fool

Topics ETFs Regulatory Compliance

The Smartest Vanguard ETF to Buy With $1,000 Right Now ↗

March 23, 2026

This ETF is built to outperform in down markets.

Via The Motley Fool

Topics ETFs

Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring ↗

March 05, 2026

Palladyne AI reported a loss of $0.04 per share, down from a loss of $1.75 per share during the same quarter a year ago, and better than Wall Street’s expectations of a loss of $0.14 per share.

Via Stocktwits

Topics Artificial Intelligence Stocks

Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗

February 24, 2026

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

Via Stocktwits

Why Did PDYN Stock Pop Over 10% In Pre-Market Today? ↗

February 03, 2026

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

Via Stocktwits

Topics Artificial Intelligence

Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗

December 19, 2025

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Via Stocktwits

Why Is CorMedix Stock Rising Today? ↗

December 18, 2025

CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.

Via Stocktwits

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗

December 17, 2025

While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg.

Via Stocktwits

JPMorgan Investment Banking Chief Plans Exit After 45 Years As Bank Ramps Up AI And Braces For $105B Costs: Report ↗

December 15, 2025

According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking.

Via Stocktwits

Topics Artificial Intelligence Retirement

Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business ↗

December 15, 2025

im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment.

Via Stocktwits

Topics Artificial Intelligence

ServiceNow Stock Is Down 5% Today — What’s Weighing On The Shares? ↗

December 15, 2025

KeyBank downgraded ServiceNow to ‘Underweight’ from ‘Sector Weight’ with a price target of $775.

Via Stocktwits

Topics Artificial Intelligence

Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook ↗

December 11, 2025

The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand.

Via Stocktwits

Topics Artificial Intelligence

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗

December 11, 2025

The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Via Stocktwits

Micron To Stop Selling Crucial Consumer Products As It Heightens Focus On Larger Customers ↗

December 03, 2025

The company said that it will continue to ship Crucial products to consumers through the end of February 2026.

Via Stocktwits

Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum ↗

November 28, 2025

Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly.

Via Stocktwits

Why ANF Stock Is Soaring Before The Bell Today? ↗

November 25, 2025

Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise.

Via Stocktwits

Micron Stock Draws Investor Attention Following A Price Target Boost From UBS ↗

November 20, 2025

UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist.

Via Stocktwits

AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗

November 19, 2025

While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios...

Via Stocktwits

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

November 18, 2025

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Via Stocktwits

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.